Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial
Pediatric Pulmonology · 2026-05 · 61 (5)
DOI: 10.1002/ppul.71677 ↗At a glance
Äquivalenzstudie in Pediatric Pulmonology, published online on 2026-05-26. Written by Nirupa Chandorkar and 7 co-authors. Institution: Department of Neonatology, National Institute of Medical Science and Research Hospital, Nims University Rajasthan, Jaipur, India. Major MEDLINE topics: Apnea, Caffeine, Central Nervous System Stimulants, Infant, Premature, Diseases. 28 references. The full text is freely available in PubMed Central.
Abstract (original language)
Objectives
While caffeine therapy is well‐established for managing apnea of prematurity (AOP), standardized protocols for its discontinuation are lacking. This study evaluated whether earlier cessation at 33 weeks postmenstrual age (PMA) is as safe as conventional discontinuation at 34 weeks.
Methods
Preterm neonates (26–32 weeks of gestation) on caffeine for AOP, who were off respiratory support and apnea‐free for 5 consecutive days by 33 weeks PMA, were randomized to early discontinuation (Group A) or conventional discontinuation at 34 weeks PMA (Group B). The primary outcome was recurrence of apnea (RAP) post‐cessation.
Results
Apnea recurrence was similar between groups (13.7% vs. 10%; OR 1.44, p = 0.71). Caffeine duration was significantly shorter in Group A (21.5 vs. 28.5 days, p = 0.024). No significant differences were noted in secondary outcomes or neonatal morbidities.
Conclusions
Early discontinuation of caffeine at 33 weeks PMA in stable preterm neonates appears safe and may reduce drug exposure without increasing apnea risk.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Neonatology, National Institute of Medical Science and Research Hospital, Nims University Rajasthan, Jaipur, India.
- Department of Pediatrics, National Institute of Medical Science and Research Hospital, Nims University Rajasthan, Jaipur, India.
ORCID profiles: Nirupa Chandorkar
Cite
APA
Chandorkar, N., Kumar, G., Singh, G., Siddiqui, K., Mittal, J. K., Singh, S., Galwa, A., & Kumar, A. (2026). Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial. Pediatric Pulmonology, 61(5). https://doi.org/10.1002/ppul.71677
Vancouver
Chandorkar N, Kumar G, Singh G, Siddiqui K, Mittal JK, Singh S, et al. Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial. Pediatric Pulmonology. 2026;61(5). doi:10.1002/ppul.71677
BibTeX
@article{Chandorkar2026,
author = {Chandorkar, Nirupa and Kumar, Gunjana and Singh, Gurnoor and Siddiqui, Kaifi and Mittal, Jai Krishan and Singh, Surendra and Galwa, Anil and Kumar, Amit},
title = {Early Versus Conventional Discontinuation of Caffeine Therapy for Apnea of Prematurity: A Randomized Controlled Trial—The DECaf Trial},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {5},
doi = {10.1002/ppul.71677}
}
EUVIMED